NewswireToday - /newswire/ -
Amherst, NH, United States, 2010/05/12 - Greystone Associates analyzes the demand factors and market dynamics behind the appearance of second- and third-generation prefillable safety devices.
The past decade has seen the injectable device segment of the drug delivery sector undergo two major evolutionary trends. The first, driven by regulatory changes aimed at protecting the wellbeing of healthcare workers, was the appearance of safety syringes. The second, propelled by the availability of powerful biological drugs manufactured by complex and capital-intensive recombinant technology, was the introduction of prefilled devices that were more economical (eliminating the need for overfilling vials) and safer (the syringe holds the correct dosage, reducing the risk of over/under dose) than vial supplied drugs. These two trends are now converging with the emergence of prefilled safety syringes – devices that merge the economics and ease-of-use of prefilled syringes and the user safety of needlestick avoidance provided by safety syringes.
As prefilled syringes have proliferated to account for a global market of more than two billion devices per year, the need to protect caregivers from cross contamination via needlestick injuries and to comply with government regulations has been primarily accomplished through the use of post-fill-and-finish add-on devices that allow the user to disable the needle after the injection event. These first-generation safety components, while mitigating the risk of inadvertent contact with a used needle, do not eliminate it. New second- and third-generation devices specifically aimed at addressing the safety issue as it pertains to prefillable syringes go beyond first-generation approaches, in many cases providing passive (no user action required) post-injection protection from contaminated needles.
We see the growth prospects of these new devices as quite positive, in spite of their higher cost relative to add-on needle disable components. The success of the customized pen injector segment has demonstrated that device cost is secondary to user expectations and patient compliance when high margin injectables are involved. We expect the use of new-generation prefillable safety syringes to track the growth of caregiver administered biological injectables beginning in 2012, much as pen-and auto injectors have done for self-administered biologicals.
More information on prefillable safety syringes can be found in a comprehensive report, researched and prepared by Greystone Associates. Prefillable Safety Syringes: Technology, Devices, Therapeutics, Strategies and Prospects examines prefillable safety syringe technology, design factors and commercial devices, provides market segment analysis and product data, analyzes important therapeutic segments and examines key regulatory, economic and competitive factors that will influence commercial success.
Greystone Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.